Related coverage linked through entity extraction aliases.
Apr 30, 2026
In TRIDENT, GMRx2 reduced recurrent stroke risk by 39% after intracerebral hemorrhage. LT3001 was safe in phase 2 acute ischemic stroke trials, supporting a global phase 3.
Jul 26, 2026
Adjunct intra-arterial alteplase after thrombectomy improved 90-day functional recovery in LVO stroke (57.5% vs 42.5%). Headache occurs in 46% of hemorrhagic stroke patients; only 21.8% of stroke/TBI patients receive inpatient rehab.
Mar 07, 2026
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
